US Patent Issued to Boehringer Ingelheim International on Nov. 18 for "FLT3 agonist antibodies and uses thereof" (Canadian Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,365, issued on Nov. 18, was assigned to Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany).

"FLT3 agonist antibodies and uses thereof" was invented by Arif Jetha (Toronto), Phil Gobeil (Toronto), Melissa Beilschmidt (Toronto), Dorothea Maetzel (Toronto) and Johan Fransson (Toronto).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are anti-FLT3 agonistic antibodies. Such agonistic antibodies are useful for the expansion of dendritic cells and the treatment of cancer."

The patent was filed on Dec. 17, 2019, under Application No. 17/413,107.

*For further information, including images, charts and tables, please visit: ...